BASEL MEDICAL GROUP LTD (BMGL) Fundamental Analysis & Valuation

NASDAQ:BMGL • VGG0864B1031

0.59 USD
-0.01 (-1.42%)
Last: Mar 6, 2026, 05:20 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BMGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, BMGL scores 2 out of 10 in our fundamental rating. BMGL was compared to 101 industry peers in the Health Care Providers & Services industry. BMGL may be in some trouble as it scores bad on both profitability and health. BMGL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. BMGL Profitability Analysis

1.1 Basic Checks

  • In the past year BMGL has reported negative net income.
  • In the past year BMGL has reported a negative cash flow from operations.
BMGL Yearly Net Income VS EBIT VS OCF VS FCFBMGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 0 -5M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -73.60%, BMGL is doing worse than 91.09% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -255.19%, BMGL is doing worse than 79.21% of the companies in the same industry.
  • BMGL's Return On Invested Capital of 10.26% is amongst the best of the industry. BMGL outperforms 80.20% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BMGL is significantly above the industry average of 9.07%.
  • The 3 year average ROIC (22.16%) for BMGL is well above the current ROIC(10.26%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -73.6%
ROE -255.19%
ROIC 10.26%
ROA(3y)-15.8%
ROA(5y)N/A
ROE(3y)-62.92%
ROE(5y)N/A
ROIC(3y)22.16%
ROIC(5y)N/A
BMGL Yearly ROA, ROE, ROICBMGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 0 -100 -200

1.3 Margins

  • BMGL has a Operating Margin of 4.53%. This is in the better half of the industry: BMGL outperforms 62.38% of its industry peers.
  • In the last couple of years the Operating Margin of BMGL has declined.
  • The Profit Margin and Gross Margin are not available for BMGL so they could not be analyzed.
Industry RankSector Rank
OM 4.53%
PM (TTM) N/A
GM N/A
OM growth 3Y-61.23%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMGL Yearly Profit, Operating, Gross MarginsBMGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025 0 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BMGL Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BMGL is creating value.
  • Compared to 1 year ago, BMGL has more shares outstanding
  • BMGL has a better debt/assets ratio than last year.
BMGL Yearly Shares OutstandingBMGL Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 5M 10M 15M
BMGL Yearly Total Debt VS Total AssetsBMGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

  • Based on the Altman-Z score of -0.39, we must say that BMGL is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.39, BMGL is doing worse than 80.20% of the companies in the same industry.
  • A Debt/Equity ratio of 0.28 indicates that BMGL is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.28, BMGL is doing good in the industry, outperforming 68.32% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z -0.39
ROIC/WACC0.95
WACC10.82%
BMGL Yearly LT Debt VS Equity VS FCFBMGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 2M -2M 4M -4M 6M

2.3 Liquidity

  • A Current Ratio of 1.23 indicates that BMGL should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.23, BMGL perfoms like the industry average, outperforming 47.52% of the companies in the same industry.
  • BMGL has a Quick Ratio of 1.19. This is a normal value and indicates that BMGL is financially healthy and should not expect problems in meeting its short term obligations.
  • BMGL has a Quick ratio of 1.19. This is comparable to the rest of the industry: BMGL outperforms 50.49% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.19
BMGL Yearly Current Assets VS Current LiabilitesBMGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BMGL Growth Analysis

3.1 Past

  • The earnings per share for BMGL have decreased strongly by -458.69% in the last year.
  • The Revenue has grown by 8.02% in the past year. This is quite good.
  • BMGL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.03% yearly.
EPS 1Y (TTM)-458.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-673.02%
Revenue 1Y (TTM)8.02%
Revenue growth 3Y2.03%
Revenue growth 5YN/A
Sales Q2Q%12.63%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMGL Yearly Revenue VS EstimatesBMGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

Find the best growth stocksShow best growing peers

1

4. BMGL Valuation Analysis

4.1 Price/Earnings Ratio

  • BMGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMGL Price Earnings VS Forward Price EarningsBMGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BMGL is valued cheaply inside the industry as 99.01% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.57
BMGL Per share dataBMGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BMGL Dividend Analysis

5.1 Amount

  • BMGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BMGL Fundamentals: All Metrics, Ratios and Statistics

BASEL MEDICAL GROUP LTD

NASDAQ:BMGL (3/6/2026, 5:20:02 PM)

0.59

-0.01 (-1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners1.58%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap11.09M
Revenue(TTM)16.35M
Net Income(TTM)-12.40M
AnalystsN/A
Price TargetN/A
Short Float %1.38%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.87
P/FCF N/A
P/OCF N/A
P/B 2.91
P/tB 2.91
EV/EBITDA 0.57
EPS(TTM)-0.52
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0.68
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -73.6%
ROE -255.19%
ROCE 12.02%
ROIC 10.26%
ROICexc N/A
ROICexgc N/A
OM 4.53%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-15.8%
ROA(5y)N/A
ROE(3y)-62.92%
ROE(5y)N/A
ROIC(3y)22.16%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)33.64%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-61.23%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA 0.71
Cap/Depr 4.64%
Cap/Sales 0.34%
Interest Coverage 1.14
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.19
Altman-Z -0.39
F-Score3
WACC10.82%
ROIC/WACC0.95
Cap/Depr(3y)2.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.21%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-458.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-673.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.02%
Revenue growth 3Y2.03%
Revenue growth 5YN/A
Sales Q2Q%12.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-90.22%
EBIT growth 3Y-60.44%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-275.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-273.12%
OCF growth 3YN/A
OCF growth 5YN/A

BASEL MEDICAL GROUP LTD / BMGL FAQ

What is the fundamental rating for BMGL stock?

ChartMill assigns a fundamental rating of 2 / 10 to BMGL.


What is the valuation status for BMGL stock?

ChartMill assigns a valuation rating of 1 / 10 to BASEL MEDICAL GROUP LTD (BMGL). This can be considered as Overvalued.


What is the profitability of BMGL stock?

BASEL MEDICAL GROUP LTD (BMGL) has a profitability rating of 3 / 10.